Predict your next investment

Private Equity
FINANCE | Investment Firms & Funds
cbridgecap.com

See what CB Insights has to offer

Investments

34

Portfolio Exits

9

Funds

4

Partners & Customers

3

About CBC Group

CBC Group is a healthcare-dedicated private equity firm that invests in China-related opportunities. The firm mainly invests in mature, leading businesses across China's major healthcare sectors including pharmaceutical/biotech, medical technology, and healthcare services.

CBC Group Headquarter Location

#22-05 Millenia Tower 1 Temasek Avenue

039192,

Singapore

+86 21 8012 7764

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CBC Group Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CBC Group Rank

Latest CBC Group News

ESR Buys Business Park in Shanghai’s Pharma Valley as First Life Sciences Asset

Jul 21, 2022

Mingtiandi Username 2022/07/21 ESR acquired the two-building campus from mainland developer Yango ESR has acquired a business park in the Shanghai biotech cluster known as Zhangjiang Pharma Valley, marking the industrial specialist’s first-ever life sciences asset. Hong Kong-listed ESR bought the two-building campus from mainland developer Yango for an undisclosed price earlier this month in partnership with Elixir, a biotech real estate firm founded by former JLL executive Jim Yip. ACGT Park has a gross floor area of 8,940 square metres (96,229 square feet) and comprises two lab buildings of four to five storeys separated by a large open garden, Yip told Mingtiandi on Thursday. The facilities are leased to eight biotech tenants, including Shanghai-based firms Antengene and GenFleet Therapeutics. “Life sciences properties have recently become a hot investment asset class in China, with a slew of investors like Gaw Capital, Warburg Pincus, APG, CBC, Hillhouse and Sequoia having announced deals or raised new funds to target the sector,” said Yip, who served as JLL’s head of capital markets for China before starting up Elixir last year. Milestone Acquisition ESR confirmed to Mingtiandi that the ACGT Park acquisition is a “major milestone” for the company as it makes a strategic entry into life sciences real estate in a bid to capture rising demand in China’s biopharma industry. Elixir founder Jim Yip The campus at 103 Cailun Road in Zhangjiang High Tech Park in Shanghai’s Pudong district forms part of Zhangjiang Pharma Valley Phase II, a 1.5 square kilometre (0.6 square mile) biomedical hub with more than 300 companies and 30 R&D centres and regional headquarters. Pharmaceutical giants Novartis, Roche, Pfizer and AstraZeneca have set up development bases in the area. Formerly called Zhangjiang Neo, ACGT Park is being rebranded with an eye towards upgrading the 2011-vintage buildings, Yip said. Shenzhen-listed Yango Group said in a recent estimate that it expected to report a loss of between RMB 3.5 billion and RMB 4.5 billion for the first half of the year. In February the developer defaulted on $657 million in offshore bonds, then it followed up in March by failing to repay RMB 600 million (then $94.62 million) in principal and interest for a domestic bond in China. Yango has yet to make a statement regarding the divestment of the property in Zhangjiang Hi-Tech Park, a popular industrial cluster in eastern Shanghai. A longtime broker at JLL and Cushman & Wakefield, Yip describes Elixir as an investment and management platform focused on providing innovative lab and R&D space and cutting-edge services for biotech companies in China. “ESR and Elixir have both expressed their strong commitment in this embryonic sector and will make further acquisitions,” he said. Healthy Interest JLL reported that 26 percent of office space leased in the Shanghai market in 2021 came from life sciences businesses — doubling the 13 percent figure achieved in 2020 — and institutional investors have taken note. Dutch pension fund manager APG teamed up last year with Singaporean investment firm CBC Group to launch a $1.5 billion venture targeting the life sciences real estate segment in Asia Pacific. The cooperation includes setting up a platform to develop and manage new healthcare projects across the region, starting with 1 million square metres of facilities in Shanghai. In April of this year, Chinese developer DNE Group announced a joint venture with a global institutional investor to pursue opportunities in life sciences parks located in top-tier cities in China, with an expected total investment of $1.2 billion. The seed project of the JV is a life sciences park owned and operated by DNE at ​​Shanghai’s Zhangjiang Science City cluster. Share this now

CBC Group Investments

34 Investments

CBC Group has made 34 investments. Their latest investment was in Sirnoax as part of their Series B on August 8, 2022.

CBI Logo

CBC Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/2/2022

Series B

Sirnoax

$200M

Yes

3

6/20/2022

Series B

Axbio

$100M

Yes

2

4/29/2022

Private Equity

Yaneng Biosciences

Yes

2

4/26/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/7/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/2/2022

6/20/2022

4/29/2022

4/26/2022

4/7/2022

Round

Series B

Series B

Private Equity

Series B

Series A

Company

Sirnoax

Axbio

Yaneng Biosciences

Subscribe to see more

Subscribe to see more

Amount

$200M

$100M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

2

2

10

10

CBC Group Portfolio Exits

9 Portfolio Exits

CBC Group has 9 portfolio exits. Their latest portfolio exit was Hugel on June 22, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/22/2022

Acq - Pending

$99M

1

9/9/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

3/17/2021

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

10/9/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/25/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/22/2022

9/9/2021

3/17/2021

10/9/2020

9/25/2020

Exit

Acq - Pending

Reverse Merger

Corporate Majority

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

CBC Group Acquisitions

1 Acquisition

CBC Group acquired 1 company. Their latest acquisition was Anrei Medical on January 06, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/6/2017

$99M

Acq - Fin

2

Date

1/6/2017

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acq - Fin

Sources

2

CBC Group Fund History

4 Fund Histories

CBC Group has 4 funds, including C-Bridge Healthcare Fund IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/12/2019

C-Bridge Healthcare Fund IV

Diversified Private Equity

Anticipated

$50M

1

7/5/2018

C-Bridge Healthcare Fund III

Subscribe to see more

Subscribe to see more

$99M

10

7/18/2017

C-Bridge Healthcare Fund II

Subscribe to see more

Subscribe to see more

$99M

10

11/30/2014

C-Bridge Healthcare Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/12/2019

7/5/2018

7/18/2017

11/30/2014

Fund

C-Bridge Healthcare Fund IV

C-Bridge Healthcare Fund III

C-Bridge Healthcare Fund II

C-Bridge Healthcare Fund LP

Fund Type

Diversified Private Equity

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Anticipated

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$50M

$99M

$99M

$99M

Sources

1

10

10

10

CBC Group Partners & Customers

3 Partners and customers

CBC Group has 3 strategic partners and customers. CBC Group recently partnered with Remilk on July 7, 2022.

CBC Group Team

14 Team Members

CBC Group has 14 team members, including current Chief Executive Officer, Wei Fu.

Name

Work History

Title

Status

Andrew L Farkas

Founder

Current

Seth Henry

Founder

Current

Wei Fu

Far East Horizon, Themes Investment Partners, Goldman Sachs, Standard Chartered, Macquarie Group, and Temasek

Chief Executive Officer

Current

Hans Kang

Chief Executive Officer, Managing Director

Current

Maverick Wong

Ping An Overseas Holdings, GIC, and Korea Technology Investment Corporation

Chief Operating Officer

Current

Name

Andrew L Farkas

Seth Henry

Wei Fu

Hans Kang

Maverick Wong

Work History

Far East Horizon, Themes Investment Partners, Goldman Sachs, Standard Chartered, Macquarie Group, and Temasek

Ping An Overseas Holdings, GIC, and Korea Technology Investment Corporation

Title

Founder

Founder

Chief Executive Officer

Chief Executive Officer, Managing Director

Chief Operating Officer

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.